FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1920-1922 November 2, 2006 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Poole, C. J. PubMed Citation

In 1976, Bonadonna and his colleagues published the results of their landmark trial of adjuvant chemotherapy for breast cancer.¹ They showed that 12 months of postoperative chemotherapy consisting of cyclophosphamide, methotrexate, and fluorouracil (CMF) decreased the risk of recurrence of breast cancer in women with positive axillary lymph nodes. Since then, many trials have been undertaken to answer important questions about adjuvant chemotherapy: What is the optimal number of drugs? What are the most advantageous doses of the agents used for adjuvant chemotherapy? How long should they be administered? Does the inclusion of an anthracycline improve the outcome? In many . . . [Full Text of this Article]

Source Information

From the Departments of Clinical Epidemiology and Biostatistics and Oncology, McMaster University, and the Juravinski Cancer Centre — all in Hamilton, ON, Canada.

This article has been cited by other articles:

• The Adjuvant Breast Cancer Trials Collaborative Gr, (2007). Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. JNCI J Natl Cancer Inst 99: 506-515 [Abstract] [Full Text]